

NB 2004.02

CERTIFICATE OF MAILING

I hereby certify that this paper or fee is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Mail Stop RCE, P.O. Box 1450, Alexandria, VA 22313-1450 on this date of May 25, 2005.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application for:

H. Michael SHEPARD et al.

Serial No.: 09/782,721

Filing Date: February 12, 2001

For: ENZYME CATALYZED
THERAPEUTIC AGENTS

Examiner: L. Crane

Group Art Unit: 1653

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**AMENDMENT AND RESPONSE TO FINAL OFFICE ACTION
ACCOMPANYING REQUEST FOR RCE**

Dear Sir:

This Amendment and Response is submitted in reply to the Final Office Action issued by the U.S. Patent and Trademark Office on September 27, 2004, in connection with the above-identified application. A response to the September 27, 2004 Office Action originally was due December 27, 2004. A Petition for a Three Month Extension of Time and Notice of Appeal were filed on March 28, 2005 (March 27, 2005 being a Sunday), making a response or other action due May 27, 2005. Accordingly, the application is pending and this RCE is properly filed.

The Amendments and Listing of the Claims begins on page 2 of this paper. The Remarks begin on page 12 of this paper.

I. AMENDMENTS


The following Listing of Claims replaces all prior listings, versions and amendments.

56. (Currently Amended) A method for inhibiting the proliferation of a hyperproliferative neoplastic cell that endogenously overexpresses thymidylate synthase, comprising contacting the cell with a ~~5'-phosphoryl or phosphoramidatyl substituted prodrug of a 5-substituted pyrimidine nucleoside or nucleotide, a derivative or a metabolite thereof that is selectively converted to a toxin in the cell by an endogenous, intracellular enzyme~~ a compound of claim 62 or a metabolite thereof formed after administration to a subject.

57. (Currently Amended) A method for treating a pathology characterized by hyperproliferative neoplastic cells that endogenously overexpresses thymidylate synthase in a subject comprising administering to the subject a ~~5'-phosphoryl or phosphoramidatyl substituted prodrug of a 5-substituted pyrimidine nucleoside or nucleotide, a derivative or a metabolite thereof that is converted to a toxin in a hyperproliferative cell by an intracellular enzyme that is endogenously overexpressed or over-accumulated in the cell~~ a compound of claim 62 or a metabolite thereof formed after administration to a subject.

58. (Canceled).

59. (Currently Amended) The method of claim ~~58~~ 56 or 57, wherein Q has the formula:




wherein ~~R₂ is selected from the group consisting of a masked phosphoryl moiety and a phosphoramidatyl moiety, and wherein R₂ and R₃ are the same or different and are independently H or OH.~~

60. (Currently Amended) The method of claim 56 or 57 ~~claim 58~~, wherein R₁ is a halogen.

61. (Currently Amended) The method of claim 56 or 57 ~~claim 58~~, wherein R₁ is of the formula $(-CH=CH)_n-R_4$, wherein n is an integer from 1 to 10, and R₄ is selected from the group consisting of ~~H a halogen, alkyl, alkenyl, alkynyl, hydroxyl, O-alkyl, O-aryl, O-heteroaryl, S-alkyl, S-aryl, S-heteroaryl, NH₂, NH-alkyl, N(alkyl)₂, NHCHO, OCN, SCN, N₃, NHOH, NHO-alkyl, and NHNH₂~~


H; hydroxyl; a halogen; -NHCHO; -OCN; -SCN; -N₃; -NH₂; -NHOH; -NHNH₂ and a C₂ to C₄ carbon-containing substituent selected from the group consisting of alkyl, alkenyl, alkynyl, -O-alkyl, -O-aryl, O-heteroaryl, -S-alkyl, -S-aryl, -S-heteroaryl, -NH-alkyl, -N(alkyl)₂ and NHO-alkyl.


62. (Currently Amended) A compound of the formula:



wherein:

R¹ is of the formula:






wherein R^2 is one of:

an unsaturated C_2 to C_4 hydrocarbyl group;


an aromatic $\text{C}_4\text{-X}$ hydrocarbyl group, wherein X is the heteroatom; or

a heteroaromatic group having the structure:



wherein J is -O-, -S-, -Se-, -NH-, or -NR^{ALK}-, wherein R^{ALK} is a linear or branched alkyl having 1 to 10 carbon atoms or a cycloalkyl group having 3 to 10 carbon atoms;

R^3 is selected from the group consisting of:










wherein R^5 may be the same or different and is independently a linear or branched alkyl group having from 1 to 10 carbon atoms, or a cycloalkyl group having from 3 to 10 carbon atoms;


wherein n is an integer from 1 to 10;

wherein m is 0 or 1;

wherein R⁴ is a toxophore selected from the group consisting of:



and




wherein X is -Cl, -Br, -I, or other halogen ~~potent leaving group~~, with the proviso that when R⁷ is -H, and M is zero, then R⁴ is not a halogen or when m is zero and n is zero, then R⁴ is not a halogen;

wherein Y is independently -H or -F;

wherein Z is independently -O- or -S-;

wherein Q is selected from the group consisting of:




wherein R⁶ is independently -H, -OH, -OC(=O)CH₃, or -O-Rg wherein Rg is a hydroxyl protecting group other than acetyl; and,

wherein R⁷ is ~~selected from the group consisting of hydrogen, a masked phosphoryl moiety and or a phosphoramidatyl~~ derivative of a naturally-occurring amino acid moiety;


and wherein said compound may be in any enantiomeric, diastereomeric, or stereoisomeric form, consisting of a D-form, L-form, α -anomeric form, and β -anomeric

form.


63. (Original) A compound according to claim 62, wherein Q is:



64. (Previously Amended) A compound of claim 62, wherein R³ is selected from the group consisting of:




65. (Previously Amended) A compound of claim 62, wherein R² is selected from the group consisting of:



66. (Original) A compound of claim 62, wherein R² and R³, taken together form a structure selected from the group consisting of:




67. (Previously Amended) A compound of claim 62, wherein R² is selected from the group consisting of:




68. (Canceled)

69. (Previously Amended) A compound of claim 62, wherein R⁷ is:




70. (Previously Amended) A compound of claim 62, wherein R⁷ is:




71. (Canceled).

72. (Canceled).


73. (Original) A compound of claim 62, wherein R⁴ is selected from the group consisting of:




74. (Original) A compound of claim 62, wherein R⁴ is selected from the group consisting of:







75. (Original) A compound of claim 62, wherein R⁴ is:




76. (Previously Amended) A compound of claim 62, wherein R⁴ is:




77. (Original) A compound of claim 62, wherein R⁴ is:



78. (Original) A compound of claim 62, wherein R⁴ is:



79. (Original) A compound of claim 62, wherein R⁴ is:



80. (Canceled).

81. (Canceled).

82. (Canceled).

83. (Canceled).

84. (Canceled).

85. (Canceled).

86. (Currently Amended) A method of inhibiting the proliferation of a pathological neoplastic cell that endogenously overexpresses an intracellular thymidylate synthase ~~target enzyme~~, comprising:

- (a) contacting the cell with a compound of claim 62 or a metabolite thereof; and
- (b) allowing the cell to take-up and selectively convert the compound from an inactive state to an active toxic by-product by means of the intracellular target enzyme.

87. (Currently Amended) A method of inhibiting the proliferation of a hyperproliferative cell that endogenously overexpresses intracellular ~~enzymes and~~

which contribute thymidylate synthase and wherein said overexpression also contributes to drug resistance, comprising:

(a) contacting the cell with the compound of claim 62 or a metabolite thereof that can be formed after administration; and

(b) allowing the cell to take-up and selectively convert the compound from an inactive state to an active toxic byproduct by means of the enzyme.

88. (Previously Amended) The method of claims 86 or 87, wherein the hyperproliferative cell is a cancer cell.

89. (Original) The method of claim 88, wherein the cancer cell is selected from the group consisting of a colorectal cell, a head and neck cancer cell, a breast cancer cell, a liver cancer cell and a gastric cancer cell.